BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 29208958)

  • 1. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
    Chen S; Dai X; Gao Y; Shen F; Ding J; Chen Q
    Sci Rep; 2017 Dec; 7(1):16922. PubMed ID: 29208958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of estrogen receptor-alpha expression in human ovarian clear cell adenocarcinoma compared with ovarian serous, endometrioid, and mucinous adenocarcinoma.
    Fujimura M; Hidaka T; Kataoka K; Yamakawa Y; Akada S; Teranishi A; Saito S
    Am J Surg Pathol; 2001 May; 25(5):667-72. PubMed ID: 11342781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Tang M; O'Connell RL; Amant F; Beale P; McNally O; Sjoquist KM; Grant P; Davis A; Sykes P; Mileshkin L; Moujaber T; Kennedy CJ; deFazio A; Tan K; Antill Y; Goh J; Bonaventura T; Scurry J; Friedlander M
    Gynecol Oncol; 2019 Sep; 154(3):531-538. PubMed ID: 31227223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
    Lax SF; Pizer ES; Ronnett BM; Kurman RJ
    Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of HER2/neu, estrogen and progesterone receptors, CA 125 and CA19-9 on cancer cell membrane in patients with serous and mucinous carcinoma of the ovary.
    Karaferic A; Jovanovic D; Jelic S
    J BUON; 2009; 14(4):635-9. PubMed ID: 20148455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progesterone reduces cell survival in primary cultures of endometrioid ovarian cancer.
    Pedernera E; Gómora MJ; Morales-Vásquez F; Pérez-Montiel D; Mendez C
    J Ovarian Res; 2019 Feb; 12(1):15. PubMed ID: 30736825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
    Matsuo K; Sheridan TB; Mabuchi S; Yoshino K; Hasegawa K; Studeman KD; Im DD; Rosenshein NB; Roman LD; Sood AK
    Gynecol Oncol; 2014 Jun; 133(3):473-9. PubMed ID: 24674832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
    McCluggage WG
    Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.
    Guan J; Xie L; Luo X; Yang B; Zhang H; Zhu Q; Chen X
    J Gynecol Oncol; 2019 Jan; 30(1):e13. PubMed ID: 30479097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunostaining Study on the Expression of NF-κB, ER, and PR in Ovarian Serous Carcinoma.
    Lin J; Xi C; Liu C; Wang Y; Liu Y; Ren C; Liu C
    Int J Gynecol Pathol; 2017 Jan; 36(1):58-63. PubMed ID: 27171541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
    Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
    Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas.
    Ordóñez NG
    Hum Pathol; 2005 Nov; 36(11):1163-7. PubMed ID: 16260268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
    Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
    Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Llaurado Fernandez M; Dawson A; Kim H; Lam N; Russell H; Bruce M; Bittner M; Hoenisch J; Scott SA; Talhouk A; Chiu D; Provencher D; Nourmoussavi M; DiMattia G; Lee CH; Gilks CB; Köbel M; Carey MS
    Gynecol Oncol; 2020 Apr; 157(1):12-20. PubMed ID: 31954537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors.
    Yasunaga M; Ohishi Y; Oda Y; Misumi M; Iwasa A; Kurihara S; Nishimura I; Okuma E; Kobayashi H; Wake N; Tsuneyoshi M
    Hum Pathol; 2009 Jul; 40(7):965-74. PubMed ID: 19269675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
    Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinoma.
    Zwart J; Geisler JP; Geisler HE
    Eur J Gynaecol Oncol; 1998; 19(3):225-8. PubMed ID: 9641218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
    Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
    Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.